Dr. Reddy's Laboratories stock trades 21.9 percent below its high

Published on 09/25/2026 at 15:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dr. Reddy's Laboratories stock traded at USD 12.24 on September 25, 2026, below its yearly high. Q1 revenue fell 5.6 percent to USD 853 million.

RDY, US2565981035, Illustration mit AI erstellt.

Dr. Reddy's Laboratories stock (ISIN US2565981035) was trading at USD 12.24 on the NYSE on September 25, 2026 at 9:43 a.m. ET, 21.9 percent below its 52-week high of USD 15.67. The immediate company calendar is an in-person Nomura meeting in Hyderabad, scheduled for September 25, 2026, according to StockTitan.

Q1 revenue fell 5.6 percent

Dr. Reddy's reported consolidated Q1 FY27 revenue of USD 853 million for the quarter ended June 30, 2026, a 5.6 percent year-over-year decline and a 7.4 percent sequential increase, according to Benzinga. The comparison shows a mixed operating picture: the quarterly top line contracted annually but improved from the preceding quarter.

Profit after tax attributable to equity holders was USD 47 million, while diluted earnings per share reached INR 5.32 in Q1 FY27, the transcript reported. EBITDA margin was 12.5 percent, compared with an adjusted 15.4 percent excluding the semaglutide API-related provision.

Semaglutide charge weighs on margins

The company recorded an INR 240 crore provision for semaglutide API-related inventory and other costs in Q1 FY27. Lower lenalidomide revenue, rejected semaglutide batches, higher solvent costs and freight expenses linked to the Middle East conflict also pressured profitability, according to Benzinga.

North America generics revenue was USD 236 million, down 41 percent year over year but up 19 percent sequentially. Management said semaglutide commercial supplies could resume in November, subject to resolving the API issue, according to the transcript.

October results date is set

Dr. Reddy's board is scheduled to meet on October 23, 2026, to consider unaudited results for the quarter ending September 30, 2026, according to StockTitan. For investors, that date creates the next quantified checkpoint after the weak June quarter and the semaglutide-related margin impact.